A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

An Open-Label, Stepwise Basal Insulin Dose Titration Study Using Continuous Subcutaneous Insulin Infusion (CSII) in Oral Antidiabetic Drug-Treated Type 2 Diabetes Mellitus Subjects Followed by a 10-Week Out-Patient Maintenance Phase

This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period. A telephone contact visit is scheduled as a follow-up for the final clinic visit. A subject's participation in this trial would be expected to be up to 16 weeks.

Inclusion Criteria:

• Type 2 diabetes diagnosis at least 2 years ago
• Body Mass Index (BMI): 26-40 kg/m^2 (both inclusive)
• HbA1c: 7.5-10% (both inclusive)
• FPG values at least 140 mg/dl (7.8 mmol/l)

Exclusion Criteria:

• Use of drugs, which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action or glucose utilization (steroids or non-specific beta-blockers)
• Current addiction to alcohol or substances of abuse or positive results on urine screen for drug and alcohol use
• Known or suspected allergy to trial products or related products